Globus Medical reports record Q4 sales $615.5M (+124% YoY); FY2024 guidance $2.45-2.475B

GLOBUS MEDICAL INC

2023-FY EPS reported $1.07 revenue$1,568,476,000

Q4 2023 sales ~$615.5M, up 124.2% as-reported, including NuVasive merger impact.
Full year 2023 sales ~$1.567B, up 53.2% as-reported over prior year.
Legacy Globus Q4 revenue $302.9M (+10.4% YoY); full year $1.152B (+12.7%).
FY2024 revenue guidance $2.450-2.475B; non-GAAP EPS guidance $2.68-$2.70.
Completed NuVasive merger Sept 1, 2023; integration on track with strong sales retention.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLOBUS MEDICAL INC updated its the three-month period and fiscal year ended December 31, 2023 guidance (initiated).

Period: the three-month period and fiscal year ended December 31, 2023
Guidance: initiated
Result: preliminary results

Exact text from the filing

On January 10, 2024, we issued a press release reporting our preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2023. The press release also included preliminary guidance for certain financial measures for the 2024 fiscal year.

View on SEC.gov

Browse all earnings releases →

GLOBUS MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001562762-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.